Molecular signal mechanisms in the development of pulmonary arterial hypertension
Pulmonary artery hypertension(PAH)is a chronic progressive disease characterized by persistent elevation of pulmonary arterial vascular pressure.The disease severely limits the function of the right ventricular,causing organ failure and finally leading to death.Despite significant advances in pharmacological treatments,PAH remains an incurable disease with high morbidity and mortality.The histopathological change of PAH is featured by remodeling of the pulmonary vascular.Abnormal proliferation of pulmonary artery smooth muscle cells(PASMCs)in peripheral vascular is one major pathological finding of pulmonary vascular remodeling.Current therapeutics available for PAH primarily aim at inhibiting the pulmonary vasoconstriction and resisting pulmonary vascular remodeling.To date,only some inhibitors targeting proliferative signaling pathways have been used to suppress the proliferation of PASMCs and reverse pulmonary vascular remodeling.However,due to serious side effects their clinical use is limited and more validation is needed before the inhibitors can be transferred into clinical use.This review will focus on signal mechanisms involved in the development of PAH from a view of cell proliferation,and give an overview of recent advances in research on inhibitors targeting proliferative pathways.
Pulmonary artery hypertension PASMCs Proliferation Signal mechanisms Signaling pathways inhibitors
Ming-xing Li De-qi Jiang Yan Wang Qing-zhuang Chen Yan-jiao Ma Shan-shan Yu Yong Wang
Department of Pharmacy,Zhu Jiang Hospital,Southern Medical University,Guangzhou 510282,China Department of Pharmacy,Zhu Jiang Hospital,Southern Medical University,Guangzhou 510282,China;Departm Department of Clinical Pharmacy,Guangzhou Hospital of Integrated Traditional and West Medicine,Guang
国内会议
广州
英文
1-15
2016-12-17（万方平台首次上网日期，不代表论文的发表时间）